Monograph Details
|
|
Gastrointestinal Tract
> Nausea
|
|
ANZEMET |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Selective 5-HT3 receptor antagonist. |
| Generic Name |
|
Dolasetron mesylate 50mg, 100mg; tabs. |
| Also |
|
• ANZEMET INJECTION
|
| Indications |
|
Prevention of nausea & vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses. Prevention of post-op nausea & vomiting. Treatment of post-op nausea +/or vomiting (IV only). |
| Children |
|
<2 yrs: not recommended. 2–16 yrs: 1.8mg/kg within 1 hr before chemotherapy; or, 1.2mg/kg within 2 hrs before surgery. Max 100mg/dose. |
| Adults |
|
≥16yrs: 100mg within 1 hr before chemotherapy or within 2 hrs before surgery. |
| Precautions |
|
Patients at risk of developing prolongation of cardiac conduction intervals, especially QTc (e.g., congenital QT syndrome, hypokalemia, hypomagnesemia); see Interactions. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Caution with drugs which can prolong ECG intervals (esp. QTc) and with cumulative high-dose anthracycline therapy. |
| Adverse Reactions |
|
Headache, dizziness, pain, fatigue, diarrhea, tachycardia, ECG changes. |
| How Supplied |
Tabs—5
Single-use vials (100mg/5mL)—1
Single-use ampules (12.5mg/0.625mL)—6
Prefilled Carpuject cartridges (12.5mg/0.625mL)—10
Multidose vial (500mg/25mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
